CytomX Therapeutics Inc(CTMX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 29 at 4:00 PM ET (Korea 10/30 05:00)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -0.46 | Insider Own | 18.91% | Shs Outstand | 217.9M | Perf Week | -6.76% |
| Market Cap | 0.50B | Forward P/E | - | EPS next Y | -20% | Insider Trans | - | Shs Float | 176.7M | Perf Month | -16.36% |
| Enterprise Value | 0.17B | PEG | - | EPS next Q | -0.07 | Inst Own | 92.53% | Short Float | 24.22% | Perf Quarter | -26.61% |
| Income | -0.08B | P/S | 27.09 | EPS this Y | -154.28% | Inst Trans | 6.34% | Short Ratio | 12.57 | Perf Half Y | -46.09% |
| Sales | 0.02B | P/B | 1.64 | EPS next 5Y | - | ROA | -28.64% | Short Interest | 42.79M | Perf YTD | -46.6% |
| Book/sh | 1.39 | P/C | 1.5 | EPS past 3/5Y | 53.93% 27% | ROE | -37.75% | 52W High | -72.29% ($8.21) | Perf Year | -30.21% |
| Cash/sh | 1.52 | P/FCF | - | Sales past 3/5Y | 12.75% -5.36% | ROIC | -26.01% | 52W Low | 5.32% ($2.16) | Perf 3Y | 112.62% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -179.91% | Gross Margin | 94.85% | Volatility(W/M) | 6.27% 6.34% | Perf 5Y | -61.64% |
| Dividend TTM | - | EV/Sales | 9.3 | Sales Y/Y TTM | -87.03% | Oper. Margin | -476.74% | ATR (14) | 0.16 | Perf 10Y | -80.4% |
| Dividend Ex-Date | - | Quick Ratio | 9.36 | EPS Q/Q | -7766.67% | Profit Margin | -451.62% | RSI (14) | 39.72 | Recom | 1.12 |
| Dividend Gr. 3/5Y | - | Current Ratio | 9.36 | Sales Q/Q | -92.4% | SMA20 | -5.47% ($2.41) | Beta | 2.2 | Target Price | $12.25 |
| Payout | - | Debt/Eq | 0.02 | Earnings | 2026/8/6 | SMA50 | -20.03% ($2.85) | Rel Volume | 1.36 | Prev Close | $2.36 |
| Employees | 69 | LT Debt/Eq | 0.01 | EPS/Sales Surpr. | -16.73% -88.55% | SMA200 | -41.42% ($3.89) | Avg Volume(3M) | 3.40M | Price | $2.28 |
| IPO | 2015/10/8 | Option/Short | Yes/Yes | Trades | 11928 | Volume | 4,628,507 | Change | -3.6% |
🧬 CytomX Therapeutics (CTMX) is a US-based clinical-stage biotech built around its Probody platform, which enables therapeutics that are selectively activated within the tumor microenvironment. The company designs antibody-drug conjugates and immunotherapies aimed at reducing toxicity in healthy tissue, and it is an oncology drug developer that continues to pursue research collaborations with multiple global pharmaceutical companies.
Over the past 1 year, on the lower side
72% below its 1-year high.
Traded more than usual. That is 136% of its average volume.
CTMX has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -154.3% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $2,709. Peers typically go for $1,237. Compared with its own 2-year average, it is 112% pricier now.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -61.6%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Short interest is a burden
24.2% of the float is sold short.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #222 of 594 in the industry
Based on market cap of $496M.
PHAT#220 Phathom Pharmaceuticals Inc $504M PER - 
OVID#221 Ovid Therapeutics Inc $500M PER - CTMX#222 CytomX Therapeutics Inc $496M PER - 
RGNX#223 Regenxbio Inc $490M PER - 
FTH#224 Faeth Therapeutics Inc $485M PER - 
FAQ
What kind of company is CTMX?
CTMX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of CTMX?
The market cap of CTMX is approximately $496M, ranking 3,174 within its sector.
What is the 52-week high and low for CTMX?
CTMX has recorded a 52-week high of $8.21 and a low of $2.16.
